Top 12 most-read articles on CNS website in 2023

Looking back at over 150 articles published on CNS (English, Hindi, Thai) in 2023 (and via CNS news wire syndication network worldwide), we are delighted to say that each of them, and the issues they focussed on, was so very important. Our heartfelt thanks to all those who shared their insights, analysis, reflections and science, evidence and rights-based viewpoints.

Here are the top 15 most-read CNS articles in 2023:

(Note: We were struggling to pick up 12 of the 15 most-read articles in 2023 but found each of them equally important. We are sharing all of them here)

• Taking TB services closer to the people in Africa is pivotal to stop TB

• Dreams of female migrant workers are often shattered, but hope remains

• Shooting our own foot: Misuse of medicines is making infections difficult to treat

• Goa to Paris: Growing call to find all TB to stop TB

• Will governments firewall public health from Big Tobacco at the upcoming FCTC Treaty meet?

• Ending TB one barangay at a time

• Will the world leaders walk the talk to end TB at the upcoming UN High Level Meeting?

• Thai key population-led organisations give hope for sustainable HIV financing

• Mumbai shows triaging those with advanced HIV disease in government centres is feasible

• Strong local actions are pivotal to reduce NCDs, TB and tobacco use in Bangladesh

• Midway to Agenda 2030: Why are we off the track on gender equality?

• When farmers choose to grow food, not tobacco, sustainable development wins

• Will lessons from COVID-19 and TB vaccine rollout improve pandemic preparedness and health security?

• It is time to get back to basics if we are to end TB

• Thai government shuts down key-population led PrEP services

Also, be welcome to read:

• Top 12 CNS podcasts in 2023
• Top 12 CNS Live sessions in 2023
• Top 12 Conferences covered by CNS in 2023
• Thanks for all CNS partners for trusting us in 2023

Looking forward to continued support in 2024 and beyond

Thanks

Team CNS

Website | YouTube | Twitter | Facebook | Instagram